Clinical trial NCT03290092: Trial of Taselisib in Overgrowth
Official title: A Multi-Centre, Open Label, Single Arm, Phase IB/IIA, Trial of Taselisib (GDC0032) in PIK3CA-Related Overgrowth
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: PIK3CA-Related Overgrowth
Lead sponsor: Centre Hospitalier Universitaire Dijon
Sponsor class: OTHER
First posted: 2017-09-21
Enrollment: 19
Sex: ALL
Minimum age (years): 16
Maximum age (years): 65
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Segmental overgrowth disorders are rare conditions characterised by abnormal growth which is usually asymmetric and confined to discrete parts of the body. We and others have identified mosaic activating mutations in the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K; encoded by the PIK3CA gene) in a subset of overgrowth disorders. The PI3K-AKT-mTOR is a critical signalling pathway, which regulates cellular growth, proliferation and survival. Activating mutations in PIK3CA lead to increased activation of the PI3K-AKT-mTORC1 axis, which in turn promotes excessive growth in affected tissue.

The PIK3CA-related overgrowth spectrum is wide, and depends upon the timing of the founder mutation in embryogenesis, and potentially upon the exact mutation. Clinical presentation ranges from isolated enlargement of a digit, to extensive overgrowth of limbs, abdomen and in some cases the brain, and may be accompanied by vascular or lymphatic malformations. Associated morbidity can be profound, with functional impairment, debilitating haemorrhages and thromboses, coupled with neurological sequelae and, in some cases, death. At present, serial debulking surgery is the only available therapeutic option.

The identification of gain-of-function mutations in PI3K has raised the possibility of treatment with drugs that inhibit PIK3CA (the p110 alpha catalytic subunit of PI3K). Taselisib is a selective inhibitor of class I PI3Ks and has direct inhibitory activity of the p110α isoform with a Kiapp value of 0.29 nmol/l.


Eligibility criteria: Inclusion Criteria:

* Have given, or their legal representative has given, written informed consent to participate
* Aged 16 years to 65 years inclusive
* Male or female
* Post-zygotic PIK3CA mutation
* Clinically stable in the opinion of the investigator
* Participant Pregnancy and contraception:

  o Female participants of child bearing potential must use an effective method of contraception during treatment and for at least 3 months after the final dose of taselisib. Acceptable methods are:
* True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the trial)
* Oral contraceptive (either combined or progestogen alone)
* Contraceptive implant, injections or patches
* Vaginal ring
* Intrauterine device (IUD, coil or intrauterine system)
* Condom and cap
* Diaphragm plus spermicide

  * A female participant of child bearing potential is defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 12 consecutive months if aged 55 years or older.
  * Men must use one of the following, reliable forms to contraception for the entire duration of treatment and for 3 months after the final dose of taselisib:
* Condom plus spermicide even if female partner is using another method of contraception (Men should also use a condom to protect male partners, or female partners who are pregnant or breast feeding, from exposure to the Trial medicine in semen).
* True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the Trial)

Exclusion Criteria:

* Pregnant or breastfeeding
* HIV infection
* Hypersensitivity to taselisib or any of its excipients
* Any current medical disorder or medication likely to impair ability to follow the trial protocol safely and effectively
* Are concurrently taking an mTOR inhibitor or any other small molecule inhibitor of the PI3K-AKT signalling pathway
* Unable or unwilling to give informed consent
* Sirolimus or taselisib treatment in 12 weeks prior to screening
* Treatment with a strong inducer or inhibitor of CYP3A4 without the possibility to stop this medication within the week prior to the screening. This includes:
* Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin
* Gastrointestinal prokinetic agents: metoclopramide.
* Antifungals: itraconazole, ketoconazole, fluconazole, voriconazole, clotrimazole
* Calcium channel blockers: verapamil, diltiazem, nicardipine
* Grapefruit containing foods/drinks
* Anticonvulsants: carbamazepine, phenobarbital, phenytoin
* Antibiotics: rifampicin, rifabutin, rifapentine
* Herbal preparations: St. John's wort (Hypericum perforatum). Other drugs: bromocriptine, cimetidine, danazol, cyclosporine, lansoprazole, calcium containing antacids.
* Inability to attend trial visits
* If less than 3 months post- major surgery at screening
* Any past medical history of inflammatory bowel disease or chronic diarrhoea of unknown aetiology
* History of type 1 or type 2 diabetes mellitus requiring insulin, GLP-1 analogues or oral hypoglycaemic agents.
* History of inflammatory bowel disease, ischemic colitis, or colitis of unknown origin.
* Fasting blood glucose \> 6.9 mmol/l
* HbA1C \> 6%
* Long QT, congenital or acquired
* Active pneumonitis
* Patients who require daily supplemental oxygen
* Inadequate renal function defined as creatinine clearance or radioisotope GFR \< 60ml/min/1.73 m²
* Inadequate liver function defined as:
* Total bilirubin \> 2.0 x ULN or conjugated bilirubin \> 2.0 x ULN for age, and
* SGPT (ALT) or SGOT (AST) ≥ 1.5 x ULN for age, and
* Serum albumin \< 30 g/L
* Inadequate fasting LDL cholesterol \> 4.2 mmol/l
* Deprived of freedom by an administrative or court order, or benefiting from a system of legal protection (tutorship, curatorship or safeguard of justice).
* Not covered by health insurance

Primary outcomes:
measure: Occurrence of dose limiting toxicities
timeFrame: less than 24 hours
Secondary outcomes:
Other outcomes:
Locations:
city: Angers
country: France
facility: CHU d'Angers
city: Bordeaux
country: France
facility: CHU de Bordeaux - GH Pellegrin
city: Dijon
country: France
facility: Chu Dijon Bourgogne
city: Garches
country: France
facility: Hôpital Raymond Poincaré (AP-HP)
city: Lille
country: France
facility: Hôpital Jeanne de Flandre
city: Lyon
country: France
facility: HCL - Hôpital femme-mère-enfant
city: Montpellier
country: France
facility: Hôpital Arnaud de Villeneuve
city: Montpellier
country: France
facility: Hôpital Saint Eloi
city: Nantes
country: France
facility: CHU Hôtel Dieu
city: Nice
country: France
facility: CHU de Nice - Hôpital l'Archet 2
city: Paris
country: France
facility: Hôpital Necker-Enfants malades
city: Rennes
country: France
facility: Hôpital Sud
city: Saint-Pierre
country: France
facility: CHU La Réunion - Site GHSR
city: Saint-Priest-en-Jarez
country: France
facility: CHU de Saint-Etienne Hôpital Nord
city: Toulouse
country: France
facility: Hôpital Larrey
city: Tours
country: France
facility: Hôpital Trousseau
city: Vandoeuvre les nancy
country: France
facility: CHU de Nancy - Hôpital de Brabois
city: Vandœuvre-lès-Nancy
country: France
facility: CHU de Nancy
Study officials:
References: